Navigation Links
New Data on Genmab and GlaxoSmithKline's Ofatumumab: Phase II Study,in Rheumatoid Arthritis to be Presented at EULAR

COPENHAGEN, Denmark; April 25, 2007 - Genmab A/S (CSE: GEN) announced today that the results of a Phase II study with ofatumumab (HuMax-CD20™) in patients with rheumatoid arthritis (RA) have been accepted for oral presentation at the 2007 Annual European Congress of Rheumatology (EULAR). The oral presentation, which will include new results from the double-blind, placebo controlled Phase II study with ofatumumab, along with data from the previous interim analysis, will be described by Professor Mikkel Østergaard, Department of Rheumatology, Copenhagen University Hospital on June 16, 2007. The abstract for the presentation will be available at www.eular.org in mid-May.

Genmab A/S and GlaxoSmithKline have a worldwide agreement to co-develop and commercialize ofatumumab.


About the study

A total of 226 patients with active RA who have previously failed one or more disease-modifying anti-rheumatic drugs (DMARDs) were enrolled in the Phase II study. Patients were randomized to one of 4 treatment groups (300 mg, 700 mg or 1000 mg of ofatumumab or placebo). Patients were permitted to continue therapy with stable doses of methotrexate and low dose prednisolone. ACR and EULAR responses were assessed in the primary intention-to-treat efficacy population at 24 weeks.


'"/>




Page: 1

Related medicine technology :

1. GlaxoSmithKline and Genmab Present Positive Phase II Results With ofatumumab in Patients With Rheumatoid Arthritis (RA)
2. Genmabs HuMax-EGFr Shows Broad Potential in Cancer Treatment
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 According to a new ... Analysis and Industry Forecast, 2014-2022," the spine bone stimulators market was valued at ... growing at a CAGR of 3.6% during the forecast period. ... ... Market Research Logo ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ Million. ... , Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... ... very strong with a total of 97 drug candidates. Pharma giant such ... involved in the development of the IPF therapeutics. The IPF pipeline comprised ... 15 are in Phase II stage, 12 are in Phase I stage, ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today announces distribution of ... current obstacles facing infection prevention and offer strategies for the health care community ... , The print component of “Fighting Infection” is distributed within the Friday, ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... According to ... score is invalid because it does not obey the rules Congress has directed the ... equivalent jobs, which the GOP reform would restore. Yet, it estimates a reduction in ...
(Date:3/24/2017)... ... March 24, 2017 , ... Shamanic healer and teacher ... Healing and Spiritual Awakening, proudly presents her Sacred Peru retreat with world ... and spiritual journey during the Summer Solstice will also be her final international ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, Cassie ... Litigation seminar in Chicago, Illinois. She will present on: , Filing Benefit ... under ERISA involve claims for long-term disability benefits. This session will address ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... enhancements, upgrading their training and leads programs. , In February, 2017, Empower Brokerage ... sales agents, Performance Partners is designed to teach how to maximize their sales ...
Breaking Medicine News(10 mins):